Blockade Medical in Irvine has been sold to Balt International in Paris on undisclosed terms.
Blockade is developing a device to treat cerebral aneurysms.
Balt makes catheters, stents and coils to treat strokes, aneurysms, and malformed arteries and veins.
Balt is owned by Bridgepoint, a private equity firm in Helsinki that purchased the company last September with an eye toward expanding its international reach.
“Blockade will nicely complement our product portfolio and will give us a strong expandable U.S.-based platform for our future development,” said Pascal Girin, President of Balt International.
Blockade had received about $9.4 million in funding over three rounds since being founded in 2011.